CompletedNCT01692782
SEP-225289 Compared With Placebo for Adult ADHD
About this title
Read the official source —Researchers compared SEP-225289 and placebo to find out how the approaches affected ADHD symptoms in adults with ADHD.
Medication studyAges 18–55United States
Understand this study
What did researchers investigate?
Researchers compared SEP-225289 and placebo to find out how the approaches affected ADHD symptoms in adults with ADHD.
Who was this study for?
This study was for people with ADHD. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.
- Listed locations
- Encino and 30 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateDecember 2012
- Recruitment status
- Completed
- Enrollment listed in the registry
- 341
- Sponsor
- Sumitomo Pharma America, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT01692782
- Official title
Show the full official title
A Randomized, Double Blind, Parallel Group, Multicenter Efficacy and Safety Study of SEP-225289 Versus Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Get this study by email
Recruitment & locations
CompletedEncino · Garden Grove · Irvine
28 more locations
- Los Alamitos
- Newport Beach
- Oceanside
- Santa Ana
- Bradenton
- Jacksonville
- Maitland
- Miami
- Oakland Park
- Sanford
- Atlanta
- Decatur
- Indianapolis
- Oklahoma City
- Rochester Hills
- Saint Charles
- Cherry Hill
- Brooklyn
- Durham
- Dayton
- Portland
- Media
- Philadelphia
- Memphis
- Austine
- Herndon
- Kirkland
- Seattle
Questions about this study
What did researchers investigate?
Researchers compared SEP-225289 and placebo to find out how the approaches affected ADHD symptoms in adults with ADHD.
Who is behind this study?
The study sponsor is Sumitomo Pharma America, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including SEP-225289 and Placebo.
Who was this study for?
This study was for people with ADHD. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.
